![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Novartis Gains Global Licensure for Respiratory Distress Cell Therapy
Novartis Gains Global Licensure for Respiratory Distress Cell Therapy
Novartis has secured the exclusive worldwide rights to Mesoblast’s investigational cell therapy, remestemcel-L, for the treatment of acute respiratory distress syndrome (ARDS) and complications arising from infection by COVID-19.
The Swiss drugmaker said it will receive an initial $50 million payment from the Australia-based regenerative medicine company, with the potential for future payments from performance-based milestones and royalties.
Remestemcel-L is currently being evaluated in a 300-person phase 3 study for COVID-19-associated respiratory issues, with Novartis hoping to launch another nonCOVID-19-linked ARDS trial upon the phase 3 study’s completion and the deal’s closure.
The therapy works by injecting mesenchymal stromal cells collected from a bone marrow donor into a patient and is meant to reduce inflammation by counteracting the cytokine storms that lead to overactive immunity.
Upcoming Events
-
21Oct